El interés en corto de Bluejay Diagnostics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Bluejay Diagnostics. Los datos de interés en corto se actualizan cada dos semanas.

Bluejay Diagnostics (NASDAQ:BJDX) Bolsa, Informe de interés en corto

Bluejay Diagnostics

Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.

Levi Strauss

News

Pre-Market Outlook

Markets

Movers

AREB

BJDX

CHSN

CVRX

GLXG

GRFX

IPDN

IVDA

KNOP

KPTI

LEVI

PRSU

SOBR

STTK

SVRE

Levi sorprende al mercado con ganancias trimestrales mejores de lo esperado y una perspectiva 2025 que mantiene sin cambios.

Acciones de Levi Strauss suben un 10%; Aquí están 20 acciones que se mueven en el premercado de EE. UU.

General

AMPY

Amplify Energy Enters Into A Definitive Agreement To Sell All Of Its Non-Operated Working Interest In Its Eagle Ford Assets To Murphy Exploration & Production Company For $23M

NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has outperformed the market over the past 20 years by 29.81% on an annualized basis producing an average annual return of 38.28%. Currently, NVIDIA has a market capitalization of $3.73 trillion. 
Buying $1000 In NVDA: If an investor had bought $1000 of NVDA stock 20 years ago, it would be worth $661,964.76 today based on a price of $152.88 for NVDA at the time of writing.
<h3>NVIDIA's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751405494_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

NVDA

Here's How Much You Would Have Made Owning NVIDIA Stock In The Last 20 Years

Stock Split

REVB

Revelation Biosciences Reveals 1-For-3 Reverse Stock Split Effective July 7, 2025

On Friday, June&nbsp;27, the Federal Reserve released the results of its 2025 Comprehensive Capital Analysis and Review ("CCAR") stress test process. Goldman Sachs expects the firm's Stress Capital Buffer ("SCB") requirement will be 3.4%, resulting in a Standardized Common Equity Tier 1 ("CET1") ratio requirement of 10.9%, effective October 1.
The Federal Reserve will provide the firm's final SCB requirement by August 31. These results and effective date may be subject to further changes pending the finalization of the Federal Reserve's outstanding proposal on SCB averaging.
In addition, the Federal Reserve disclosed that the firm's current SCB, from the CCAR 2024 test, has been reduced by 10&nbsp;basis points to 6.1%. This results in a current CET1 ratio requirement of 13.6%, effective immediately.

Goldman Sachs Expects 2025 Stress Capital Buffer Of 3.4% And Common Equity Tier 1 Requirement Of 10.9% Starting October; Federal Reserve Lowers Goldman Sachs' Current SCB To 6.1%, Setting CET1 Requirement At 13.6%, Effective Immediately

The firm's capital plan includes a 33% increase in the common stock dividend from $3.00 to $4.00 per share beginning July 1, 2025, subject to approval by the firm's Board of Directors at the customary third quarter meeting. This increase is a continuation of the firm's plan to pay shareholders a sustainable and growing dividend.

Dividends

Goldman Sachs Group Intends To Increase Its Common Stock Dividend From $3.00 To $4.00 Per Share Beginning July 1, 2025

Centene Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares are tumbling in Tuesday&#8217;s after-hours session after the health care company withdrew its <a href="https://www.benzinga.com/pressreleases/25/07/n46208548/centene-corporation-withdraws-2025-guidance">guidance for 2025</a>.
What Happened: Centene withdrew its previous 2025 earnings guidance and all underlying guidance elements based on the company&#8217;s preliminary interpretation of marketplace data from the independent actuarial firm Wakely.
The company said that overall market growth in 22 of the company&#8217;s 29 marketplace states is lower than previously expected and implied aggregate market morbidity in those states is significantly higher than the company&#8217;s assumptions for risk adjustment revenue transfer.
Centene&#8217;s preliminary analysis of the days resulted in an estimated reduction of its previous full-year net risk adjustment revenue transfer&nbsp;expectations of approximately $1.8 billion, representing an adjusted earnings impact of approximately $2.75 per share. 
&#8220;The Company does not have information or estimates for its remaining seven Marketplace states, but anticipates, due to the morbidity trends observed in the 22 states, an additional reduction to its net risk adjustment revenue transfer expectation with a corresponding adjusted diluted EPS impact,&#8221; the company said.
Centene noted that it began the process of refiling 2026 marketplace rates to reflect a higher projected baseline of marketplace morbidity than previously expected.&nbsp;
Centene said its Medicaid business has experienced a step-up in medical cost trends. As a result, the company expects the Medicaid Health Benefits Ratio in the second quarter to be higher than the&nbsp;first quarter. Centene also said its Medicare Advantage and Medicare Prescription Drug Plan businesses are performing above expectations in the&nbsp;second quarter.
Centene expects to report <a href="https://www.benzinga.com/calendars/earnings">second-quarter results</a> on July 25. The company will provide additional insights at that time. 
CNC Price Action: <a href="http://benzinga.com/quote/CNC">Centene shares</a> were down 21.80% at $44.30 in after-hours Tuesday at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/movers/25/07/46202931/12-health-care-stocks-moving-in-tuesdays-intraday-session">12 Health Care Stocks Moving In Tuesday&#8217;s Intraday Session</a></li>
</ul>
Photo: JHVEPhoto/Shutterstock.com

Guidance

Health Care

After-Hours Center

Centene Withdraws 2025 Guidance, Shares Dive

On June 27, 2025, the Federal Reserve released the results of its 2025 bank stress test, which underscore BNY's resilient business model and strong balance sheet. The Federal Reserve also notified the company that its preliminary Stress Capital Buffer ("SCB") requirement will remain 2.5%, equal to the regulatory floor. This SCB is expected to be effective from October 1, 2025, to September 30, 2026, under the current capital plan rule. Since the introduction of the SCB requirement in 2020, BNY's SCB has consistently remained at the 2.5% floor. The company does not anticipate any impact on its SCB requirement based on the Federal Reserve's notice of proposed rulemaking to reduce the volatility of the SCB requirement issued on April 17, 2025.

BNY's Stress Capital Buffer To Remain At 2.5% Floor Through 2026

Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) has outperformed the market over the past 5 years by 9.35% on an annualized basis producing an average annual return of 23.62%. Currently, Energy Transfer has a market capitalization of $61.33 billion. 
Buying $1000 In ET: If an investor had bought $1000 of ET stock 5 years ago, it would be worth $2,886.55 today based on a price of $17.87 for ET at the time of writing.
<h3>Energy Transfer's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751404523_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Energy Transfer Stock In The Last 5 Years

Riot Platforms, Inc. ("Riot") issues this press release pursuant to Part 3 of Canadian National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues and Part 5 of Canadian National Instrument 62-104 – Take-Over Bids and Issuer Bids in respect of Bitfarms Ltd. ("Company").
Riot announces that on July 1, 2025 it sold 2,802,484 common shares (the "Sold Shares") of the Company representing approximately 0.50% of the issued and outstanding Common Shares (the "Common Shares") of the Company (based on the information contained in the Company's management information circular filed on June 9, 2025 (the "Company's Circular").
The Sold Shares were sold through normal course sales on the Nasdaq Stock Market and other open market trades for a weighted average price of approximately US$0.84 per Sold Share (equivalent to approximately C$1.14 per Sold Share based on the daily exchange rate posted by the Bank of Canada on June 30, 2025 (the "Exchange Rate")) at a price range per Sold Share of approximately US$0.82 to US$0.86&nbsp;(equivalent to approximately C$1.12 to C$1.18 based on the Exchange Rate) for an aggregate amount equal to US$2,349,042.09 (equivalent to approximately C$3,204,798.12 based on the Exchange Rate).
Immediately prior to the sales of Common Shares giving rise to the issuance of this press release, Riot beneficially owned 71,110,860 Common Shares, representing approximately 12.79% of the issued and outstanding Common Shares (based on the information contained in the Company's Circular). Following completion of the aforementioned sales, Riot beneficially owned 68,308,376 Common Shares, representing approximately 12.29% of the issued and outstanding Common Shares as at the date hereof (based on the information contained in the Company's Circular).

Asset Sales

BITF

RIOT

Riot Platforms Sells 2,802,484 Bitfarms Shares At An Average Price Of $0.84/Share, For $2.35M, Reducing Stake From 12.79% To 12.29% In Open Market Transactions

The Bank of New York Mellon Expects To Increase Its Quarterly Cash Dividend On Its Common Shares From $0.47 To $0.53 Per Share, Commencing As Early As Q3 Of 2025

Management

Bank of Hawai'i Promotes Bradley "Brad" S. Satenberg To CFO

Alpha Cognition Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) (&quot;Alpha Cognition&quot; [ACI], or the &quot;Company&quot;), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The data provides additional evidence of benefits of ALPHA-1062, in the treatment of mTBI resulting from repetitive blast trauma, a highly relevant military injury. Service related mTBI results in a high incidence of persistent physical and emotional challenges for patients, impacting their quality of life and that of their families. Additionally, a history of mTBI increases the risk of dementia diagnosis later in life.
Data analysis for this study, supported by the US Department of Defense and conducted in collaboration with US Department of Veterans Affairs investigators and the Seattle Institute of Biomedical and Clinical Research, has been concluded, demonstrating that ALPHA-1062 administration following blast induced mTBI, results in a notable reduction in indices of TBI associated neuropathology.
ALPHA-1062 administration reduced the brain levels of three toxic forms of a brain protein Tau. One of these forms (pTau 217) has been suggested to identify TBI patients at greater risk of long-term cognitive decline. It is also one of the earliest emerging biomarkers in Alzheimer&#39;s disease. A second form of toxic Tau (pTau-S202/T205) can be found in very early-stage pathology in the brains of Alzheimer&#39;s patients before the appearance plaques and tangles. The third form (pTau 231) is elevated in early Alzheimer&#39;s disease and TBI. Taken together, reduction of these toxic forms of pTau suggests a potential role for ALPHA-1062 in the treatment of TBI and that this may additionally positively impact the risk of later developing Alzheimer&#39;s disease.
Additional benefits of ALPHA-1062 were observed following blast trauma. High dose ALPHA-1062 reduced the numbers of myeloid cells which play a critical role in neuroinflammation and tissue repair, as well as the number of astrocytes, which regulate neurotransmitters like glutamate and GABA to support neuronal health. These changes are consistent with reduced neuroinflammation following ALPHA-1062 administration. Finally, nerve growth factor receptor expression, which plays an important role in neuronal survival, was increased in an ALPHA-1062 dose-dependent manner. &quot;These outcomes are in agreement with those of an earlier pre-clinical study in a moderate TBI animal model, both studies demonstrated protective effects of ALPHA-1062, providing support for the continued development of ALPHA-1062 for the treatment of traumatic brain injury,&quot; said Denis Kay, ACI&#39;s Chief Scientific Officer.
Alpha Cognition&#39;s next steps in this program will be to complete formulation of ALPHA-1062 for sublingual administration and conduct a bridging pharmacokinetic study vs. ZUNVEYL&reg; (Benzgalantamine) and an existing intranasal formulation of ALPHA-1062.

Biotech

ACOG

Alpha Cognition Reveals Pre-Clinical Data For ALPHA-1062 Use In A Military Relevant Model Of Repetitive Mild Traumatic Brain Injury; Data Provides Additional Evidence Of Benefits Of ALPHA-1062, In The Treatment Of MTBI Resulting From Repetitive Blast Trauma

Boqii Holding  Plans To Cease The Listing Of Its American Depositary Shares On The NYSE American; The Company Will Implement A 1-For-160 Reverse Stock Split Effective on July 11, 2025

American Bitcoin expected to trade on Nasdaq under the ticker symbol "ABTC"
MIAMI and LAS VEGAS, July 1, 2025 /PRNewswire/ -- American Bitcoin Corp. ("American Bitcoin" or the "Company"), a Bitcoin accumulation platform focused on building America's Bitcoin infrastructure backbone, and Gryphon Digital Mining, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) ("Gryphon"), an innovative venture in the Bitcoin mining space, today announced the filing of an amended registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") in connection with their previously announced stock-for-stock merger transaction (the "Transaction").

IPOs

GRYP

American Bitcoin Expected To Trade On Nasdaq Under Ticker Symbol "ABTC" Following Stock-For-Stock Merger With Gryphon Digital Mining

American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) today announced that the Federal Reserve set the company's preliminary Stress Capital Buffer ("SCB") requirement at 2.5 percent, effective October 1, 2025 through September 30, 2026, based on the results of the 2025 Comprehensive Capital Analysis and Review process. This is the minimum SCB requirement under the applicable regulations and is consistent with American Express' previously disclosed SCB in effect through September 30, 2025.

American Express's Preliminary Stress Capital Buffer Set At 2.5%

<h3>Gainers</h3>
<ul>
<li>Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) shares increased by 7.4% to $1.75 during Tuesday's after-market session. The company's market cap stands at $41.6 million. </li>
<li>Jianzhi Education Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) shares increased by 6.66% to $1.76. The market value of their outstanding shares is at $1.2 million. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) shares rose 5.54% to $0.95. The market value of their outstanding shares is at $1.8 million. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) shares moved upwards by 4.98% to $0.77. The company's market cap stands at $78.9 million. </li>
<li>Sypris Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYPR#NASDAQ">SYPR</a>) shares rose 4.95% to $2.12. The market value of their outstanding shares is at $50.7 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock moved upwards by 4.76% to $2.2. The company's market cap stands at $6.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) stock declined by 14.4% to $0.14 during Tuesday's after-market session. The market value of their outstanding shares is at $11.7 million. </li>
<li>EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) stock declined by 9.35% to $0.29. The market value of their outstanding shares is at $1.8 million. As per the press release, H1 earnings came out today. </li>
<li>Hour Loop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) stock fell 5.67% to $1.5. The company's market cap stands at $50.2 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock declined by 5.56% to $1.19. The company's market cap stands at $14.7 million. </li>
<li>Nova Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVFY#NASDAQ">NVFY</a>) shares decreased by 4.97% to $1.34. The company's market cap stands at $18.9 million. </li>
<li>Monro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) stock fell 4.95% to $15.18. The market value of their outstanding shares is at $446.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EZGO

HOUR

KXIN

MNRO

NVFY

PRPL

SYPR

TLYS

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) shares moved upwards by 24.0% to $5.99 during Tuesday's after-market session. The market value of their outstanding shares is at $38.9 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares increased by 18.7% to $3.11. The company's market cap stands at $4.4 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) stock moved upwards by 8.69% to $0.77. The company's market cap stands at $40.4 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock increased by 8.56% to $0.73. The company's market cap stands at $51.4 million. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) shares increased by 6.95% to $0.34. The market value of their outstanding shares is at $11.2 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock moved upwards by 6.45% to $1.65. The company's market cap stands at $2.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares fell 20.5% to $45.03 during Tuesday's after-market session. The market value of their outstanding shares is at $27.0 billion. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares fell 17.14% to $1.7. The company's market cap stands at $4.1 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) stock fell 12.79% to $0.3. The company's market cap stands at $6.6 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares decreased by 9.55% to $0.28. The company's market cap stands at $13.3 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares fell 9.29% to $9.48. The company's market cap stands at $250.5 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares fell 8.09% to $0.25. The market value of their outstanding shares is at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASBP

DBVT

GNPX

MBIO

MODD

OGEN

PLUR

VERO

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) shares increased by 10.3% to $5.37 during Tuesday's after-market session. The company's market cap stands at $1.2 billion. </li>
<li>Greenbrier Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) shares increased by 10.08% to $51.74. The company's market cap stands at $1.4 billion. As per the press release, Q3 earnings came out today. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) stock increased by 6.71% to $0.07. The market value of their outstanding shares is at $1.7 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) shares increased by 6.66% to $0.24. The company's market cap stands at $46.9 million. </li>
<li>TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) shares increased by 6.64% to $0.95. The market value of their outstanding shares is at $41.8 million. </li>
<li>Tigo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) shares rose 5.26% to $1.4. The market value of their outstanding shares is at $79.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) shares fell 28.4% to $7.98 during Tuesday's after-market session. The company's market cap stands at $5.5 million. </li>
<li>BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) stock fell 8.55% to $15.41. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Nuburu (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) stock fell 7.7% to $0.36. The market value of their outstanding shares is at $21.7 million. </li>
<li>Intercont (Cayman) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCT#NASDAQ">NCT</a>) shares fell 4.91% to $3.88. The market value of their outstanding shares is at $89.2 million. </li>
<li>Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) stock declined by 4.86% to $1.96. The company's market cap stands at $58.8 million. </li>
<li>Performance Shipping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSHG#NASDAQ">PSHG</a>) stock decreased by 4.71% to $1.62. The company's market cap stands at $21.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGLC

BURU

EOSE

PSHG

SCWO

SHIM

TPIC

TYGO

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>HeartCore Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) shares rose 16.7% to $0.49 during Tuesday's after-market session. The market value of their outstanding shares is at $10.8 million. </li>
<li>Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) shares increased by 11.24% to $20.68. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) stock rose 8.3% to $0.98. The company's market cap stands at $63.9 million. </li>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) stock moved upwards by 7.54% to $1.14. The market value of their outstanding shares is at $9.2 million. </li>
<li>Datavault AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>) stock rose 4.53% to $0.69. The market value of their outstanding shares is at $44.4 million. </li>
<li>ScanTech AI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) shares rose 4.24% to $0.66. The company's market cap stands at $13.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) stock decreased by 13.9% to $0.32 during Tuesday's after-market session. The market value of their outstanding shares is at $11.8 million. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) stock declined by 12.16% to $0.11. The company's market cap stands at $17.0 million. </li>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) stock fell 10.9% to $40.99. The company's market cap stands at $205.5 million. </li>
<li>Actelis Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) shares fell 10.53% to $0.51. The company's market cap stands at $5.5 million. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares declined by 5.25% to $2.35. The company's market cap stands at $1.0 billion. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) stock declined by 4.99% to $0.38. The company's market cap stands at $11.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBK

ASNS

BMNR

CMBM

DVLT

HTCR

IFBD

Next Technology Holding Inc. - Ordinary Shares

NXTT

STAI

VRNT

12 Information Technology Stocks Moving In Tuesday's After-Market Session

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus Tech" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>), a leading global intelligent and luxury mobility provider, today announced that Etika Automotive Sdn Bhd ("Etika") exercised its put option on June 30, 2025, requiring us to purchase 49% of the equity interests in Lotus Advance Technologies Sdn Bhd ("Lotus UK") held by Etika pursuant to the Put Option Agreement dated January 31, 2023 between the parties.
Lotus UK is currently owned by Geely International (Hong Kong) Limited ("Geely HK") and Etika. As announced on April 14, 2025, Geely HK exercised a similar put option granted to it by the Company. With Etika having exercised its put option, the Company is expected to acquire 100% of the equity interests of Lotus UK through non-cash transactions based on pre-agreed prices. Upon completion, the Company will gain control over Lotus UK and consolidate its financial results. The strategic transaction will enable the Company to integrate all businesses and operations under the Lotus brand.
Lotus UK controls the manufacturing operations of Lotus' sportscars and hyper cars, and Lotus Engineering which provides comprehensive consultancy services to many of the OEMs and Tier 1 suppliers around the world.
The acquisition is expected to be completed by 2025, subject to potential regulatory approvals.
In conjunction with the business combination between the Company and L Catterton Asia Acquisition Corp, a special purpose acquisition company affiliated with L Catterton, a leading global consumer-focused investment firm, the Company and Lotus UK entered into a Put Option Agreement with each of Geely HK and Etika. Pursuant to these agreements, each of Geely HK and Etika was granted the right to require the Company to acquire its equity interest in Lotus UK at a pre-agreed pricing method1 and upon satisfaction of the condition ("Put Option Exercise Condition") that the total number of vehicles sold by Lotus UK and its subsidiaries shall exceed 5,000 in 2024, with the exercise of such options by Geely HK and Etika not cross-conditioned on one another. As of December 31, 2024, the Put Option Exercise Condition had been satisfied.
Note 1: Pursuant to the agreement, the Company will issue new shares valued at $10 per share in consideration of Geely HK and Etika's transfer of Lotus UK shares. Lotus UK is valued at 1.15 multiples revenue plus cash minus debt of LGIL, based on LGIL's audited consolidated annual financial report of 2024.

Lotus Technology Expects To Acquire 100% Equity Interest Of Lotus Advance Technologies Through Non-Cash Transactions Based On Pre-Agreed Prices; The Acquisition Is Expected To Be Completed By 2025; No Financial Terms Disclosed

Press Releases

Bitech Technologies (OTCQB: BTTC) Appoints Montgomery Bannerman to Drive Strategic Growth in Renewable Energy – see other stocks inside….

Bluejay Diagnostics Announces Reverse Stock Split

Financing

Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Comments

Bluejay Diagnostics

Interés en corto

Bluejay Diagnostics (NASDAQ:BJDX) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL